Orgenesis

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Orgenesis (NASDAQ:ORGS) Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care (POC) treatment of patients at Johns Hopkins. Construction work is planned to start in the second quarter of 2022 and the facility is expected to be operational in 2Q 2023.

Orgenesis and Johns Hopkins University to create Maryland center for cell therapy manufacturing

Center will expand Orgenesis' Point of Care (POCare) Platform Capabilities in Maryland Center will expand Orgenesis' Point of Care (POCare) Platform Capabilities in Maryland

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance.

Orgenesis-Theracell Joint Venture Secures €32M Grant From Greek Government

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platform consists of three core elements: POCare Therapeutics, POCare Technologies, and POCare Network What Orgenesis (NASDAQ:ORGS) does: OrGenesis (TSX:GDC) Inc. is focused on unlocking the potential of personalized therapies and closed processing systems through its cell and gene therapy platform. Cell and gene therapies (CGTs) use modified cells or cellular matter to treat, prevent or cure serious health issues.

Orgenesis leading the charge at an exciting time for cell therapy

Orgenesis (NASDAQ:ORGS) Inc announced that its joint venture (JV) with Theracell Advanced Biotechnology SA in Greece has been designated a “Priority Investment of Strategic National Importance.”   The global biotech company noted that the designation was awarded by Enterprise Greece, the official Greek national investment and trade promotion agency, which is responsible for the allocation of the government funds.

Orgenesis and Theracell JV to receive up to €32M from Greek government to accelerate the rollout of therapies

Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.

Orgenesis enters collaboration agreement with Tel Aviv Sourasky Medical Center to establish point-of-care cell therapy center

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc announced a more than five-fold increase in third-quarter revenue as it continues to roll out its Point of Care (POCare) platform.  The global biotech company, which is focused on unlocking the full potential of cell and gene therapies (CGTs), also reported a strong rise in revenue for the first nine months of its financial year to September 30, 2021, to $28.6 million, compared to just $5.3 million for the same period last year.

Orgenesis reports 425% surge in 3Q revenue as POCare platform gains scale

Orgenesis to host conference call today at 8:30AM ET Orgenesis to host conference call today at 8:30AM ET

Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Thursday, November 4, 2021 to discuss the Company's corporate progress and other developments.

Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

Orgenesis Inc announced a new collaboration with biotech firm Savicell Diagnostics Ltd to accelerate the development and manufacturing of its cell and gene therapy platform. The wide-ranging agreement sees Orgenesis using Savicell's immunometabolism platform to help advance its own platforms on a number of fronts.

Orgenesis strikes collaboration agreement with Savicell Diagnostics to advance its cell and gene therapy platform

Goal to accelerate development, QC testing and manufacturing  of Orgenesis' cell and gene therapy platform

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

GERMANTOWN, MD / ACCESSWIRE / August 12, 2021 / Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Thursday, August 19 at 8:00 am ET. Vered Caplan, CEO of Orgenesis, will be hosting the presentation and answering questions from investors.

Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

The stock price of Orgenesis Inc (NASDAQ: ORGS) increased by 3.53%. This is why it happened.

ORGS Stock Price Increased 3.53%: Why It Happened

Orgenesis Inc said its 2Q 2021 revenues rose from $1.75 million to $10.5 million compared to the same period in 2020.  The international biotech company, which is focused on unlocking the full potential of cell and gene therapies (CGTs) in an affordable and accessible format, credited the Orgenesis Point of Care (POCare) Platform as a key factor to the profit boost.

Orgenesis sees 2Q 2021 revenue jump by 500% year-over-year

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Thursday, August 5, 2021 to discuss the Company's corporate progress and other developments.

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced multiple milestones in the development of Ranpirnase for multiple indications, including anogenital warts, adenoviral conjunctivitis and even coronavirus (COVID-19).  First, Orgenesis has completed its pre-Investigational New Drug (IND) consultation with the US Food and Drug Administration (FDA), discussing RanTop (Ranpirnase topical gel) for the treatment of anogenital warts (AGW).

Orgenesis says Ranpirnase advancing towards multiple indications after FDA consultation and presentation of positive results

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced that enrollment has commenced for a clinical trial using the company's Tissue Genesis Icellator in rotator cuff repair surgeries at the Hospital for Special Surgery (HSS) in New York.  The Phase 2 trial, supported by the National Stem Cell Foundation and an Orthopedic Research and Education Foundation grant, will evaluate the safety and efficacy of autologous stromal and vascular fraction cells (SVF) that are injected after surgical rotator cuff repair.

Orgenesis says enrollment is underway for a Phase 2 rotator cuff repair study of its Tissue Genesis Icellator

Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgery Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgery

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator cuff repair

GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the Summer Solstice Conference, hosted by The MicroCap Rodeo, being held virtually on June 1st – June 4th, 2021.

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

Orgenesis is a mispriced and misunderstood biotechnology with a pipeline of over 30 licensed gene and cell therapies and a platform called Orgenesis Mobile Processing Labs. Due to reinvestment plans and two one-off expenses, the financials looked terrible on a superficial level. This spooked many investors and it created mispricing in the stock.

Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q1 2021 Results - Earnings Call Transcript

The stock price of Orgenesis Inc (NASDAQ: ORGS) increased by over 10% during intraday trading. This is why it happened.

ORGS Stock: Over 10% Increase Intraday Explanation

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, reported a four-fold increase in revenue in its first quarter to end-March, as the company continues its journey to build a long-term profitable business with its Point of Care (POCare) strategy.   Revenue in the three months came in at $9.4 million, up from $1.8 million in the first quarter of 2020.

Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy

Achieves operating profit for the first quarter of 2021

News for Orgenesis Stock (ORGS)